This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Sep;23(9):990-992.

doi: 10.1016/S1473-3099(23)00231-1. Epub 2023 Jun 13.

Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout

Ingrid Chen¹, Deus S Ishengoma²

Affiliations

Affiliations

¹ University of California, San Francisco, CA 94158, USA. Electronic address: ingrid.chen@ucsf.edu.
² National Institute for Medical Research, Dar Es Salaam, Tanzania; Harvard TH Chan School of Public Health, Boston, MA, USA; Faculty of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.

PMID: 37327810
DOI: 10.1016/S1473-3099(23)00231-1

Comment

Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout

Ingrid Chen et al. Lancet Infect Dis. 2023 Sep.

. 2023 Sep;23(9):990-992.

doi: 10.1016/S1473-3099(23)00231-1. Epub 2023 Jun 13.

Authors

Ingrid Chen¹, Deus S Ishengoma²

Affiliations

¹ University of California, San Francisco, CA 94158, USA. Electronic address: ingrid.chen@ucsf.edu.
² National Institute for Medical Research, Dar Es Salaam, Tanzania; Harvard TH Chan School of Public Health, Boston, MA, USA; Faculty of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.

PMID: 37327810
DOI: 10.1016/S1473-3099(23)00231-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. We thank Timothy Wells for insights on the malaria drug development pipeline.

Comment on

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.
Ogutu B, Yeka A, Kusemererwa S, Thompson R, Tinto H, Toure AO, Uthaisin C, Verma A, Kibuuka A, Lingani M, Lourenço C, Mombo-Ngoma G, Nduba V, N'Guessan TL, Nassa GJW, Nyantaro M, Tina LO, Singh PK, El Gaaloul M, Marrast AC, Chikoto H, Csermak K, Demin I, Mehta D, Pathan R, Risterucci C, Su G, Winnips C, Kaguthi G, Fofana B, Grobusch MP. Ogutu B, et al. Lancet Infect Dis. 2023 Sep;23(9):1051-1061. doi: 10.1016/S1473-3099(23)00209-8. Epub 2023 Jun 13. Lancet Infect Dis. 2023. PMID: 37327809 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey